Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||CD274 positive|
|Therapy||Capecitabine + Oxaliplatin + Pembrolizumab|
|Indication/Tumor Type||gastroesophageal junction adenocarcinoma|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|CD274 positive||gastroesophageal junction adenocarcinoma||sensitive||Capecitabine + Oxaliplatin + Pembrolizumab||Guideline||Actionable||Keytruda (pembrolizumab) in combination with first-line chemotherapy including Xeloda (capecitabine) and Eloxatin (oxaliplatin), is included in guidelines as preferred first-line therapy for patients with gastroesophageal junction adenocarcinoma expressing PD-L1 (CD274, CPS>=10), and without ERBB2 (HER2) overexpression (category 2A), and as first-line therapy for patients with PD-L1 expression (CD274, CPS <10) and without ERBB2 (HER2) overexpression (category 2B) (NCCN.org).||detail...|
|PubMed Id||Reference Title||Details|